Effects of Cognitive & Emotional Functioning on Treatment Outcomes

Status Withdrawn

Clinical Trial Summary

The investigators are interested about the degree to which individuals can persist with individualized treatment goals when their cues (external such as food, or internal such as anxiety) are high for impulsive/maladaptive behavior (e.g., purging, not eating, etc.). The investigators want to find specific high-difficulty situations in which to assess whether participants remain mindful of the big picture and are willing to work toward therapeutic goals. Also, the investigators want to rate the participants degree of success (e.g., proportion of calories eaten) assessed more objectively.

The theory is that working memory capacity (WMC) modulates the ability to keep longer-term goals in mind when faced by current stress/temptations. For example, the ability to control drinking when one has an implicit urge to drink is predicted by WMC. The ability to apply a novel emotional regulation skill at a time of stress is also predicted by WMC. Indeed, the generic ability to pursue goals in the future (as assessed by the discounting of the value of future goals) is reliably predicted by WMC. There is also evidence that activation of brain regions associated with WMC (by direct activation of the dorsolateral prefrontal cortex via transcranial magnetic stimulation (TMS), or by having a person complete a relevant cognitive task) improves delay discounting.

Accordingly, the investigators are proposing a study that both assesses the link between WMC and relevant the clinical measures noted above, as well as changes in these measures following activation of WM with a cognitive prime (WM task). The overall design calls for an initial WMC assessment, followed by randomization to complete 3 days of a WM prime and then 3 days of a no prime group, or vice versa. The investigators then assess the clinical outcomes noted above across the following 6 days, with a WM prime first or no prime first occurring prior to the targeted behaviors. The investigators will prime WM prior to participant's evening meal, with the WM intervention offered during the free time before this meal.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03050632
Study type	Interventional
Source	Boston University Charles River Campus
Contact
Status	Withdrawn
Phase	N/A
Start date	September 2019
Completion date	December 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05656859` - Prevalence of Eating Disorders Among Patients in the Department of Health Promotion
Completed	`NCT04085861` - Mental Health in Dancers; an Intervention Study	N/A
Recruiting	`NCT05651295` - A Precision Medicine Approach to Target Engagement for Emotion Regulation	N/A
Enrolling by invitation	`NCT04174703` - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing	N/A
Terminated	`NCT04278755` - Binge Eating & Birth Control	Phase 2
Completed	`NCT02484794` - Augmenting Specialty Eating Disorder Clinical Treatment With a Smartphone Application	N/A
Completed	`NCT02567890` - Swedish Body Project for Prevention of Eating Disorders	N/A
Completed	`NCT02252822` - Improving Treatment Engagement for Adolescents With Bulimia Nervosa	N/A
Completed	`NCT02021344` - Mental Health First Aid for College Students	N/A
Completed	`NCT00601354` - Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder	N/A
Completed	`NCT00418977` - Comparing the Effectiveness of Two Therapies to Treat Signs of Anorexia Nervosa in Adolescents	N/A
Completed	`NCT00304187` - Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa	Phase 2
Completed	`NCT00733525` - Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa	N/A
Active, not recruiting	`NCT04779216` - Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa	Phase 3
Completed	`NCT04433663` - Eating Disorders, Self Regulation and Mentalization	N/A
Recruiting	`NCT05509257` - Naltrexone Neuroimaging in Teens With Eating Disorders	Early Phase 1
Completed	`NCT04509531` - Building Resilience in Cyberbullying Victims	N/A
Recruiting	`NCT05730348` - Mealtime Anxiety in Eating Disorders
Enrolling by invitation	`NCT05814653` - A Study to Evaluate Primary Care Treatment for Adolescent Eating Disorders	N/A
Completed	`NCT04506216` - Eating Disorders in Type 1 Insulin-dependent Diabetes Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effects of Cognitive and Emotional Functioning on Treatment Outcomes — CEO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms